Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Neuropathic Pain Stakeholder Insight Neuropathic Pain neuralgia

VIEWS: 28 PAGES: 5

									Brochure
More information from http://www.researchandmarkets.com/reports/54466/




Stakeholder Insight: Neuropathic Pain - Comparative Overview of
Treatment Preferences Across the Seven Major Markets

Description:    IntroductionFollowing the success of Pfizer's blockbuster Neurontin (gabapentin), interest in the
                neuropathic pain market has grown exponentially. The market will continue to grow unabated over
                the next ten years primarily due to increased public and physician awareness and new drug
                launches, including generic gabapentin.ScopeAnalysis based on The Neuropathic Pain Insight
                survey of over 594 physicians in the US, Japan, France, Germany, Italy, Spain, and the UKReferral
                patterns by indication by country, and treatment of five neuropathic pain types and fibromyalgia
                Analysis of the attributes of current treatments, with an overview of late stage pipeline products
                and physician awareness of these future treatmentsPhysician perception of strategic issues
                including clinical trial design, unmet needs, and marketing, and the 'indication versus symptoms'
                debateReport HighlightsThe current neuropathic pain market suffers from lack of public awareness,
                poor physician education (often leading to misdiagnosis), under-utilization of effective drugs,
                inappropriate use of medications, and regional variations in drug availability.Datamonitor believes
                the 'indication versus symptoms' debate is one of the most important issues in the current market.
                Datamonitor recommends existing and potential players consider the pros and cons of regulatory
                agency viewpoint and rulings across the seven major markets.Branded products can continue their
                dominance of the market, supported by aggressive promotional campaigns and astute marketing
                and product positioning strategies. However, with generic gabapentin entering the market, more
                than ever companies need to be innovative to effectively define and claim market share.Reasons to
                PurchaseGain a better understanding of the challenges faced by existing and future players in the
                neuropathic pain marketPredict future trends in the treatment of neuropathic pain and how to
                capitalize on forthcoming changes in treatment practiceTarget lucrative areas of the market as
                defined by physicians, such as fibromyalgia, and understand why these areas offer commercial
                opportunityRegion: US, Japan, France, Germany, Italy, Spain, and the UK



Contents:       About Datamonitor healthcare 2About the CNS pharmaceutical analysis team 2Chapter 1 Executive
                summary 31.1 Scope of the Analysis 31.2 Datamonitor insight into neuropathic pain 3The current
                neuropathic pain market suffers from lack of public awareness, poor physician education (often
                leading to misdiagnosis), under-utilization of effective drugs, inappropriate use of medications, and
                regional variations in drug availability. Datamonitor believes these are but some of the challenges
                facing existing and future players in the market. 5The US neuropathic pain market 5The Japanese
                neuropathic pain market 6The European neuropathic pain market 7Although frequently managed
                with the same treatments, Datamonitor believes it is important that investors are aware of the
                opportunities and drawbacks of key subtypes in order to optimize product positioning and
                marketing strategies. Particularly as this aligns with the FDA licensing strategy. 8Diabetic
                neuropathic pain: a large, growing yet competitive market 8Post-herpetic neuralgia: an opportunity
                to leverage into other niche markets 9Neuropathic-low-back pain: large patients numbers but poor
                awareness 10Fibromyalgia: a large opportunity for SNRI antidepressant companies 11HIV
                associated neuropathic pain: good awareness and uptake of pain therapies 13Trigeminal neuralgia:
                an established market with limited commercial opportunity 13Datamonitor believes the ‘indication
                versus symptoms’ debate is one of the most important issues in the current market. Datamonitor
                recommends existing and potential players consider the pros and cons of regulatory agency
                viewpoint and rulings across the seven major markets. 13Indication-specific labeling in the US and
                Japan 14Broad neuropathic pain labeling in Europe 15The goal is to find a shared mechanism
                16Aggressive promotional campaigns and astute marketing and product positioning strategies will
                ensure branded products can dominate the market. With generic gabapentin entering the market,
                more than ever companies need to be innovative to effectively define and ‘own’ a market.
                Datamonitor has identified several realistic ways of differentiating a new product from gabapentin.
                17The neuropathic market will continue to grow unabated over the next ten years primarily due to
                increased public and physician awareness and new drug launches. Pfizer is expected to continue
                leading the market in terms of revenues with new entrant pregabalin. However, competition will be
                strong as several top-tier players aim to enter the market with novel and existing compounds.
                18Only watertight trials will convince physicians to change their prescribing habits 19Targeted
                research will guarantee long-term market growth 19The future market will be saturated with top-
tier players 19Assuming pregabalin is launched, Pfizer will reign supreme 201.3 Neuropathic Pain
Insight: methodology 20Chapter 2 Introduction 332.1 Overview of the Neuropathic Pain Insight
Study 332.2 Sample 34Chapter 3 Patient Potential 353.1 Introduction 353.2 Etiology 36Diabetic
neuropathic pain 36Trigeminal neuralgia 37Post-herpetic neuralgia 37Neuropathic low-back pain
37Fibromyalgia 38Diagnosis of fibromyalgia 39HIV neuropathic pain 403.3 Epidemiology of
neuropathic pain 413.4 Diagnosis 45Breakdown of diagnosis by physician type 45Chapter 4
neuropathic pain treatment 474.1 Introduction 474.2 Referral and assessment 484.3
Pharmacotherapy 52Antidepressants 53Tricyclic antidepressants 53Newer antidepressants
54Anticonvulsants 54Local anesthetics 55Opioids 55Topical agents 564.4 Importance of therapeutic
endpoints on prescribing decisions 564.5 Summary of neuropathic treatment in the seven major
markets 57First-line therapy 58Second-line therapy 59Third-line therapy 604.6 Summary of
treatment—Country comparison 61US 61Gabapentin: High off-label use despite labeling for an
individual subtype 61Generic gabapentin expected in H1 2004 61Strong market potential for
antidepressants 61Endo’s Lidoderm popular for PHN 61New peer-reviewed guidelines: no to
NSAIDs, yes to opioids 62Japan 63Treatment significantly different from US and Europe 63Nerve
blocks are current gold standard 63Over-utilization of NSAIDs 64Europe 644.7 Summary of
treatment—Indication comparison 66Overview 66Diabetic neuropathic pain 67Overview of DNP
treatment 67Gabapentin 67Amitriptyline 69Lidocaine patch 69NSAIDS 70Mexiletine 70Epalrestat
71Liponacid/Alpha-lipoic acid 71Datamonitor summary 72Trigeminal neuralgia 73Overview of TN
treatment 73Carbamazepine 73Gabapentin 74Datamonitor summary 74Post-herpetic neuralgia
74Overview of PHN treatment 74Gabapentin 75Lidocaine patch 75Datamonitor summary
76Neuropathic low-back pain 77Overview of NLBP treatment 77Gabapentin 78NSAIDs
78Amitriptyline 79Datamonitor summary 80Fibromyalgia 81Overview of fibromyalgia treatment
81Gabapentin 81Amitriptyline 81Venlafaxine 82Other antidepressants 82NSAIDs 83Datamonitor
summary 83HIV associated neuropathic pain 84Overview of HIVNP treatment 84Gabapentin
84Lidocaine patches 85Amitriptyline 85Datamonitor summary 854.8 Combination therapy
86Introduction 87Gabapentin + amitriptyline 87Gabapentin + opioid 87There is no single popular
combination in Japan 88Polytherapy will remain key to neuropathic pain treatment 884.9 The
commercial potential of interventional techniques in neuropathic pain 89Implantable systems
89Medtronic’s Synergy neurostimulation system for NLBP 89A niche market 90Chapter 5 Drug
Analysis 925.1 Symptoms of neuropathic pain 925.2 Non-symptom attributes in neuropathic pain
945.3 Drug attributes 955.4 Drug profiles 96Methodology 96Efficacy 97Non-efficacy criteria
98Overall score 100Gabapentin 100Lidocaine patch 5% 103Opioids 104Carbamazepine
107Amitriptyline 1075.5 R&D drugs 108Physician awareness of pipeline products 108Late stage
pipeline overview 112Pregabalin 112Milnacipran 113Memantine 114Trend towards a mechanistic
approach 115Metabotropic glutamate modulators 116NMDA antagonists 117Selective sodium
channel blockers 118Chapter 6 Strategic Issues In Neuropathic Pain 1206.1 Clinical trial design
120Clinical endpoints 12150% reduction in pain 121Side effects 122Placebo effect 122Length of
trial 1226.2 Indications versus symptoms 122Most physicians prefer companies to target the
symptoms of neuropathic pain 122Indication-specific labeling in the US and Japan 124For a broad
indication the FDA requires proof of a shared mechanism 124FDA pushes basic research 124Pros
and cons of the FDA ruling 125Off-label prescribing is less common in Japan, which limits patient
potential 125Broad neuropathic pain labeling in Europe 126The goal is to find a shared mechanism
1276.3 Unmet needs 128More effective, better tolerated drug 128Low cost drug 129Increasing
pressure from healthcare payers 129Need to define and own a market 1296.4 Marketing
neuropathic pain compounds 130Off-label ‘promotion’ 130Chapter 7 Appendix A 1327.1
Bibliography 132References 132General information 132Epidemiology 133Clinical trials
134Websites 1407.2 Drug profile tables 1417.3 Contributing experts 144Neuropathic pain experts
145Professor John D Loeser MD 145Professor Kazuo Hanaokam MD 145Professor Cesare Fieschi MD
145Professor Henry J McQuay MD 145Professor Praveen Anand MD 145Professor Shuji Dohi MD
145Professor Andreas Straube MD 145Professor Giorgio Sandrini MD 146Assistant Professor Brian D
Loftus MD 146Associate Professor Barth L Wilsey MD 146Dr Gockel MD 146Dr Gary J McCleane MD
146Dr Philippe Poulain MD 146Dr Ricardo Ruiz-Lopez MD 146Diabetic neuropathic pain experts
146Dr Charles H Ripp MD 146Post-herpetic neuralgia experts 147Dr David Bowsher MD
147Neuropathic low-back pain experts 147Dr Justin C Riutta MD 147Fibromyalgia experts 147Dr
Derek Enlander MD 147Dr Delong MD 147Dr Ducloux MD 147Professor Vignon MD 147HIV
neuropathic pain experts 148Professor Lauren Shaiova MD 148Professor Donald I Abrams MD
148Dr Nicola E Mackie MD 1487.4 Physician research methodology 148Introduction 148Our
research partners 150Research objectives 150Questionnaire development 152Research
methodology 153Data processing 155Quality control 1567.5 Neuropathic Pain Insight Questionnaire
156Chapter 8 Appendix B 1718.1 About Datamonitor 171About Datamonitor Healthcare
171Datamonitor Healthcare’s research and analysis methodologies 1728.2 Datamonitor
Healthcare’s therapy area capabilities 172About the CNS analysis team 173Datamonitor
            Healthcare’s Consulting expertise 174Datamonitor’s Therapeutic Consulting expertise 175Key
            therapy team members 175Lynda Lynch, Director CNS 175David Abramson, Therapeutic Lead
            Consultant 176About the Author 176Ben Greener, Senior CNS Analyst. 176Disclaimer 178



Ordering:   Order Online - http://www.researchandmarkets.com/reports/54466/

            Order by Fax - using the form below

            Order by Post - print the order form below and sent to

                         Research and Markets,
                         Guinness Centre,
                         Taylors Lane,
                         Dublin 8,
                         Ireland.
                                                           Page 1 of 2

Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-
1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct.


               Product Name:           Stakeholder Insight: Neuropathic Pain - Comparative Overview of Treatment
                                       Preferences Across the Seven Major Markets
               Web Address:            http://www.researchandmarkets.com/reports/54466/
               Office Code:            OC8HNNSTUQNXX

Product Format
Please select the product format and quantity you require:


                                   Quantity

               Electronic:               EURO €17,677.00




Contact Information
Please enter all the information below in BLOCK CAPITALS


      Title:                  Mr              Mrs            Dr          Miss             Ms         Prof

      First Name:                                                 Last Name:

      Email Address: *

      Job Title:

      Organisation:

      Address:

      City:

      Postal / Zip Code:

      Country:

      Phone Number:

      Fax Number:

     * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
                                                              Page 2 of 2

Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

          Pay by credit card:                     American Express

                                                  Diners Club

                                                  Master Card

                                                  Visa
                                           Cardholder's Name

                                           Cardholder's Signature

                                           Expiry Date

                                           Card Number

                                           CVV Number

                                           Issue Date
                                           (for Diners Club only)




          Pay by check:                    Please post the check, accompanied by this form, to:

                                           Research and Markets,
                                           Guinness Center,
                                           Taylors Lane,
                                           Dublin 8,
                                           Ireland.


                                           Please transfer funds to:
          Pay by wire transfer:
                                           Account number                   833 130 83
                                           Sort code                        98-53-30
                                           Swift code                       ULSBIE2D
                                           IBAN number                      IE78ULSB98533083313083
                                           Bank Address                 Ulster Bank,
                                                                        27-35 Main Street,
                                                                        Blackrock,
                                                                        Co. Dublin,
                                                                        Ireland.


     If you have a Marketing Code please enter it below:


           Marketing Code:


      Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
     http://www.researchandmarkets.com/info/terms.asp



                                              Please fax this form to:
                                  (646) 607-1907 or (646) 964-6609 - From USA
                          +353 1 481 1716 or +353 1 653 1571 - From Rest of World

								
To top